NCT05394233 2022-05-27
Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
Sichuan Cancer Hospital and Research Institute
Tianjin Medical University Cancer Institute and Hospital